Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
2026: The year AI’s role in pharma shifts from analysis to action
2026: The year AI’s role in pharma shifts from analysis to action
FDA conflicts of interest extend beyond adcomm experts
FDA conflicts of interest extend beyond adcomm experts
BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
Hemophilia gene therapies are struggling on the market, even as innovation soars
Hemophilia gene therapies are struggling on the market, even as innovation soars The business case for hemophilia gene therapy still isn’t adding up due to persistent m...
4 major changes at the FDA this year
4 major changes at the FDA this year The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies. Published Dec. 3,...
Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons
Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-ta...
A drugmaker charts a path through pharma’s ethical minefields
A drugmaker charts a path through pharma’s ethical minefields
Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian
Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian
Along with NIH cuts come risks to patient safety and scientific data
Along with NIH cuts come risks to patient safety and scientific data
4 takeaways from pharma’s manufacturing boom
4 takeaways from pharma’s manufacturing boom
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
What’s next in the eye disease pipeline?
What’s next in the eye disease pipeline? An early gene therapy breakthrough spurred investments, but can the industry maintain momentum? Published Nov. 24, 2025 By Kell...
Pharma faces a critical ‘turning point’ in 2026, years in the making
While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.
How do Big Pharma employees rate their CEOs?
There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish the...
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
Developing a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
The next leap in Alzheimer’s R&D is coming, but not around the corner
While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page